Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$138.57 USD

138.57
932,038

-2.88 (-2.04%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $138.52 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 249)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

RingCentral, Tapestry, JD.com, DaVita and Aercap highlighted as Zacks Bull and Bear of the Day

RingCentral, Tapestry, JD.com, DaVita and Aercap highlighted as Zacks Bull and Bear of the Day

Here's Why You Should Invest in DaVita (DVA) Stock For Now

DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.

John Blank headshot

Challenges for Monetary Policy: Global Week Ahead

Big-name retailers take center stage. Major department store earnings continue to disappoint. However, big-box retailers may tell us a different story about retail.

Is DaVita (DVA) a Profitable Stock for Value Investors Now?

Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.

Kinjel Shah headshot

5 Price-to-Book Value Picks to Improve Portfolio Returns

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Trina Mukherjee headshot

Outlook for Outpatient and Home Healthcare Industry Looks Bright

Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.

The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita

The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita

DVA or CHE: Which Is the Better Value Stock Right Now?

DVA vs. CHE: Which Stock Is the Better Value Option?

Nalak Das headshot

5 Safe Picks Amid Yield Inversion and Geopolitical Concerns

Throughout this month, U.S. stock markets are witnessing extreme volatility. Equities are suffering as investors are flocking to safe-haven sovereign bonds.

Zacks.com featured highlights include: DaVita, Kraton, ADT, Universal Forest Products and International Game

Zacks.com featured highlights include: DaVita, Kraton, ADT, Universal Forest Products and International Game

Why DaVita HealthCare (DVA) Might be Well Poised for a Surge

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

John Blank headshot

A Time to Shift Gears: Zacks August Strategy

The latest Q2 GDP report showed us that the consumer is solid, but business fixed investment is lackluster.

The Zacks Analyst Blog Highlights: Industrial Logistics, Medpace, Unitil, DaVita and Telephone and Data

The Zacks Analyst Blog Highlights: Industrial Logistics, Medpace, Unitil, DaVita and Telephone and Data

Anindya Barman headshot

5 Value Picks Boasting Strikingly Low EV/EBITDA Ratios

We have screened value stocks based on EV/EBITDA ratio, which offers a clearer picture of a company's valuation and earnings potential.

Nilanjan Choudhury headshot

Relative Price Strength Make These 5 Stocks Worth a Look Now

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Nalak Das headshot

5 Stocks to Buy on a Possible Second Rate Cut in September

As signs of deterioration emerge, the central bank may feel compelled to cut rate for the second time in September.

Stock Market News For Aug 5, 2019

Benchmarks closed in the red on Friday to post their worst single-day decline in a month.

Stock Market News for Aug 02, 2019

Benchmarks closed lower on Thursday after President Trump announced plans to impose additional tariffs on imports from China.

DaVita (DVA) Earnings Beat, Revenues Miss Estimates in Q2

DaVita (DVA) completes divestment of DMG unit to Optum for $4.34 billion.

DaVita HealthCare (DVA) Q2 Earnings Top Estimates

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 10.91% and -0.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

6 Promising Price-to-Book Value Stocks to Buy in August

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.

Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.

Cigna (CI) to Report Q2 Earnings: What's in the Offing?

Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.

Is a Beat in the Cards for Humana's (HUM) Earnings in Q2?

Humana's (HUM) second-quarter earnings are likely to gain traction from a solid revenue stream.

What's in the Cards for DaVita (DVA) This Earnings Season?

DaVita (DVA) projects operating income within $460-$465 million for the second quarter.